Paul Tudor Jones's KLRA Position Overview
Paul Tudor Jones (via Tudor Investment Corp Et Al) currently holds 48,050 shares of Kailera Therapeutics, Inc. (KLRA) worth $1.06 M, representing 0.00% of the portfolio. First purchased in 2026-Q2, this recently established position has been held for 1 quarters.
Based on recent 13F filings, Paul Tudor Jones has initiated a new position in KLRA, representing a fresh investment thesis on this company. Insufficient history to summarize additions or reductions.
Analysis based on 13F filings available since 2013 Q2
Paul Tudor Jones's Kailera Therapeutics (KLRA) Holding Value Over Time
Track share changes against reported price movement
Quarterly Kailera Therapeutics (KLRA) Trades by Paul Tudor Jones
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2026 | +48,050 | New Buy | 48,050 | $22.03 |
Paul Tudor Jones's Kailera Therapeutics Investment FAQs
Paul Tudor Jones first purchased Kailera Therapeutics, Inc. (KLRA) in Q2 2026, acquiring 48,050 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Paul Tudor Jones has held Kailera Therapeutics, Inc. (KLRA) for 1 quarters since Q2 2026.
Paul Tudor Jones's largest addition to Kailera Therapeutics, Inc. (KLRA) was in Q2 2026, adding 48,050 shares worth $1.06 M.
According to the latest 13F filing for Q2 2026, Paul Tudor Jones's firm, Tudor Investment Corp Et Al, owns 48,050 shares of Kailera Therapeutics, Inc. (KLRA), valued at approximately $1.06 M.
As of the Q2 2026 filing, Kailera Therapeutics, Inc. (KLRA) represents approximately 0.00% of Paul Tudor Jones's publicly disclosed stock portfolio, making it one of their key holdings.
Paul Tudor Jones's peak holding in Kailera Therapeutics, Inc. (KLRA) was 48,050 shares, as reported at the end of Q2 2026.